Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for Compass Therapeutics (CMPX) over the last 5 years, with Dec 2024 value amounting to $137.6 million.

  • Compass Therapeutics' Shares Outstanding (Weighted Average) rose 0.50% to $138.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.3 million, marking a year-over-year increase of 0.50%. This contributed to the annual value of $137.6 million for FY2024, which is 7.92% up from last year.
  • Latest data reveals that Compass Therapeutics reported Shares Outstanding (Weighted Average) of $137.6 million as of FY2024, which was up 7.92% from $127.5 million recorded in FY2023.
  • In the past 5 years, Compass Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $137.6 million in FY2024 and a low of $5.0 million during FY2020.
  • For the 3-year period, Compass Therapeutics' Shares Outstanding (Weighted Average) averaged around $130.4 million, with its median value being $127.5 million (2023).
  • Data for Compass Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 88.08% (in 2021) over the last 5 years.
  • Compass Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $5.0 million in 2020, then reached $52.1 million in 2020, then soared by 88.08% to $98.0 million in 2021, then climbed by 28.73% to $126.2 million in 2022, then grew by 1.03% to $127.5 million in 2023, then climbed by 7.92% to $137.6 million in 2024.